Publications by authors named "Aisaku Ota"
VN-0200 is an investigational β-glucan-CpG-adjuvanted respiratory syncytial virus (RSV) vaccine (antigen: VAGA-9001a [RSV F glycoprotein], adjuvant: MABH-9002b). This multicenter, randomized, double-blind, dose-finding phase 2 study explored the optimal VN-0200 dose and confirmed its humoral and cellular immunity and safety. In total, 342 healthy Japanese participants aged 60 to 80 years were randomized to one of 10 vaccination groups, each receiving a different combination of VAGA-9001a and MABH-9002a.
View Article and Find Full Text PDFArticle Synopsis
- DS-5670 is an mRNA vaccine targeting the spike protein of SARS-CoV-2, showing safety and effectiveness in adults for COVID-19 booster vaccination.
- A study with children aged 5-11 years assessed a third booster of either DS-5670a/b or bivalent BNT162b2 after initial vaccination, measuring blood neutralization response to variants.
- Results indicated DS-5670a/b produced a comparable immune response to BNT162b2, exceeding safety benchmarks with no new safety concerns noted among the pediatric participants.